isocitrate dehydrogenase/рак

Линкът е запазен в клипборда

Изберете тип сортиране

Страница 1 от 43 резултата

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Among the most notable cancer genome-wide sequencing discoveries in recent years was the finding of mutation hot-spots in the isocitrate dehydrogenase (IDH) genes in grade II/III astrocytomas and oligodendrogliomas and in secondary glioblastomas. This was rapidly followed by identification of

Metabolic Characterization of Space Occupying Lesions of the Brain

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Introduction - Recently the first commercially available 7T MR-scanner which is approved for clinical use came on to the market. The main motivation to go to higher field strengths is the fact that better SNR can be achieved in shorter acquisition time, or higher spatial resolution can be obtained

Foci of Tumor Heterogeneity in Diffuse Low-Grade Gliomas

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

IDH1-mutated gliomas are slow-growing brain tumors which progress into high-grade gliomas. The early molecular events causing this progression are ill-defined. Previous studies revealed that 20% of these tumors already have transformation foci. These foci offer opportunities to better understand

Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

The patients with primary glioblastoma multiforme (GBM) have high mortality and morbidity. Even with best conventional therapy (surgery, radiation, and chemotherapy), the most of median survivals are less than 2 years. The one-year progression-free survival (PFS) is less than 20%. Recently, the

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

PRIMARY OBJECTIVES: - To evaluate the safety of IDH-1 inhibitor FT-2102 (FT-2102) in combination with CDA inhibitor E7727/decitabine combination agent ASTX727 (ASTX727) in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients with IDH1 R132 mutations. (Phase Ib) - To evaluate the

Utility of Primary Glioblastoma Cell Lines

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Glioblastoma (GBM) is the most aggressive type of brain tumor arising from glial cells accounting for 52% of all parenchymal brain cancer cases and 20% of all intracranial tumors. GBM has pronounced mitotic activity, substantial tendency toward neoangiogenesis (microvascular proliferation),

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Patients with documented IDH mutations will be screened for eligibility within 4 weeks of the start of study treatment including medical history, physical exam, height, weight, vital signs, performance status, routine blood lab tests, pregnancy test, ECG, and tumor measurements for safety, and

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

PRIMARY OBJECTIVES: I. To determine the overall response rate (ORR) to olaparib in subjects with isocitrate dehydrogenase (IDH)1/2 mutant myelodysplastic syndrome (MDS) or IDH1/2-mutant acute myeloid leukemia (AML). SECONDARY OBJECTIVES: I. To establish the progression free survival (PFS) of

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Background: - Glioma is the most common malignant brain tumor. Genes coding for isocitrate dehydrogenase (IDH), a metabolic enzyme, are frequently mutated in gliomas, particularly lower-grade gliomas (LGGs). IDH mutation causes a unique tumor biology, including the accumulation of 2-hydroxyglutarate

Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

IDHm HGGs (High-Grade (grade III or IV) Gliomas that harbor mutations in Isocitrate Dehydrogenase 1 (IDH1) or Isocitrate Dehydrogenase 2 (IDH2)) most frequently occur in young adults. Favorable prognostic factors include high Karnofsky performance score, young age, 1p/19q codeletion and

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

PRIMARY OBJECTIVES: I. Determine the safety and tolerability of the combination of Poly (ADP-Ribose) polymerase (PARP) inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA) subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Myelodysplastic syndrome (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenia, especially anemia, and often evolving to Acute myeloblastic Leukemia (AML). Main prognostic factors of MDS, for progression to AML and survival, include

Nivolumab in People With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND: - Glioma is the most common malignant brain tumor. Genes coding for isocitrate dehydrogenases 1and 2 (IDH1 and IDH2), metabolic enzymes, are frequently mutated in gliomas, particularly lower-grade gliomas (LGGs). IDH1/2 mutation causes a unique tumor biology, including the accumulation

Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

The principal objective of this study is the metabolic characterization of pediatric solid tumors, with a particular focus on neuroblastoma (NBL) and fusion positive sarcoma (FPS), which will allow the detection of tumor specific metabolic alterations that can be exploited with the aim of developing

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Scientific justification: Gliomas are the most frequent brain tumors. Prognosis is poor. It depends on the histological grade (I to IV), and on the molecular profile, and particularly on the presence of IDH (Isocitrate dehydrogenase) mutation which is associated with a better prognosis. Mutations of

Предишна
1
2
3
Следваща

Присъединете се към нашата
страница във facebook

Herbal & Natural Medicine

Най-пълната база данни за лечебни билки, подкрепена от науката

Работи на 55 езика
Билкови лекове, подкрепени от науката
Разпознаване на билки по изображение
Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
Прочетете научни публикации, свързани с вашето търсене
Търсете лечебни билки по техните ефекти
Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания